HTB homepage • Conference reports • Articles by subject • Subscribe 14 March 2018 Contents Editorial 14 March 2018: vol 19 no 5 – CROI 2018 part 1 Conference reports 25th Conference on Retroviruses and Opportunistic Infections (CROI 2018) Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment Twice-daily dolutegravir is effective and tolerable with rifampicin Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin Efavirenz 400 mg can be given with anti-tuberculosis treatment Bictegravir at CROI 2018: switching studies and drug resistance analyses PrEP at CROI 2018 (part 1): Access in Australia and the US PrEP at CROI 2018 (part 2): Animal studies for future drugs BHIVA best of CROI feedback workshops Antiretrovirals FDA approves ibalizumab in the US to treat multidrug HIV resistance PDFs 14 March 2018: vol 19 no 5 HTB homepage • Conference reports • Articles by subject • Subscribe
